SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-1
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(D)(1)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
and
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)
CORVITA CORPORATION
(Name of subject company)
HPG ACQUISITION CORP.
PFIZER INC.
(Bidders)
Common Stock, $.001 par value
(Title of class of securities)
221010 10 1
(CUSIP number of class of securities)
Paul S. Miller, Esq.
Senior Vice President and General Counsel
Pfizer Inc.
235 East 42nd Street
New York, New York 10017-5755
(212) 573-2323
(Name, address and telephone number of person authorized to receive notices
and communications on behalf of bidders)
Copies to:
Dennis J. Block, Esq.
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, New York 10153
May 14, 1996
(Date of event which requires filing of this statement)
* Constituting the Final Amendment to Schedule 14D-1.
Page 1 of 7 Pages
Exhibit Index is located on Page 6
<PAGE>
SCHEDULE 14D-1
- ------------------------- -------------------
CUSIP No. 221010 10 1 Page 2 of 7 Pages
- ------------------------- -------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
HPG Acquisition Corp.
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
13-3888930
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
AF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) OR 2(f)
N/A [_]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Florida
- --------------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,918,487 shares
- --------------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES CERTAIN SHARES
N/A [_]
- --------------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)
96.6%
- --------------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON
CO
- --------------------------------------------------------------------------------
Page 2 of 7 Pages
<PAGE>
SCHEDULE 14D-1
- ------------------------- --------------------
CUSIP No. 221010 10 1 Page 3 of 7 Pages
- ------------------------- --------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
Pfizer Inc.
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
13-5315170
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
OO
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) OR 2(f)
N/A [_]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
- --------------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,918,487 shares
- --------------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES CERTAIN SHARES
N/A [_]
- --------------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)
96.6%
- --------------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON
CO
- --------------------------------------------------------------------------------
Page 3 of 7 Pages
<PAGE>
Pfizer Inc. ("Parent") and its direct wholly-owned subsidiary, HPG
Acquisition Corp. ("Purchaser"), hereby amend and supplement as set forth herein
their Tender Offer Statement on Schedule 14D-1 and their Beneficial Ownership
Statement on Schedule 13D, originally filed on April 17, 1996, relating to the
offer by Purchaser to purchase all outstanding shares of common stock, par value
$.001 per share (the "Shares"), of Corvita Corporation, a Florida corporation
(the "Company").
Item 6. Interest in Securities of the Subject Company.
(a)-(b) A copy of Parent's press release, dated May 15, 1996, announcing
the expiration of the Offer and acceptance for payment of the Shares tendered
pursuant thereto and its plans to effect a merger of Purchaser with and into the
Company is attached hereto as Exhibit (a)(8), and the complete text thereof is
incorporated herein by reference.
Item 11. Material to Be Filed as Exhibits.
(a)(1) Offer to Purchase, dated April 17, 1996* (a)(2) Letter of Transmittal*
(a)(3) Notice of Guaranteed Delivery*
(a)(4) Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other
Nominees*
(a)(5) Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust
Companies and Other Nominees*
(a)(6) Guidelines for Certification of Taxpayer Identification Number on
Substitute Form W-9*
(a)(7) Form of Summary Advertisement, dated April 17, 1996*
(a)(8) Text of Press Release of Pfizer Inc., dated May 15, 1996
(c)(1) Agreement and Plan of Merger, dated as of April 11, 1996, among Parent,
Purchaser, and the Company*
(c)(2) Shareholders Agreement, dated as of April 11, 1996, among Parent,
Purchaser, and the Selling Shareholders*
(c)(3) Promissory Note, dated April 11, 1996, from the Company to Parent (c)(4)
Letter Agreement, dated April 11, 1996, from Parent to the Company
relating to the loan to the Company
(c)(5) License Agreement, dated April 11, 1996, between Parent and the Company
(c)(6) Joint Press Release, dated April 11, 1996, by Parent and the Company
(c)(7) Confidentiality and Standstill Agreement, dated August 16, 1995, between
Dillon, Read & Co. Inc., on behalf of the Company, and Parent
(d) None
(e) Not Applicable
(f) None
- --------------------
* Previously Filed
Page 4 of 7 Pages
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: May 15, 1996 PFIZER INC.
By: /s/ PAUL S. MILLER
Name: Paul S. Miller
Title: Senior Vice President and
General Counsel
HPG ACQUISITION CORP.
By: /s/ GEORGE A. STEWART
Name: George A. Stewart
Title: President
Page 5 of 7 Pages
<PAGE>
EXHIBIT INDEX
Exhibit Description Page
(a)(1) Offer to Purchase, dated April 17, 1996.............................*
(a)(2) Letter of Transmittal.............................................. *
(a)(3) Notice of Guaranteed Delivery.......................................*
(a)(4) Letter to Brokers, Dealers, Commercial Banks, Trust Companies and
Other Nominees......................................................*
(a)(5) Letter to Clients for use by Brokers, Dealers, Commercial Banks,
Trust Companies and Other Nominees................................. *
(a)(6) Guidelines for Certification of Taxpayer Identification Number on
Substitute Form W-9.................................................*
(a)(7) Form of Summary Advertisement, dated April 17, 1996.................*
(a)(8) Text of Press Release of Pfizer Inc., dated May 15, 1996............7
(c)(l) Agreement and Plan of Merger, dated as of April 11, 1996, among
Parent, Purchaser, and the Company..................................*
(c)(2) Shareholders Agreement, dated as of April 11, 1996, among Parent,
Purchaser, and the Selling Shareholders.............................*
(c)(3) Promissory Note, dated April 11, 1996, from the Company to Parent...*
(c)(4) Letter Agreement, dated April 11, 1996, from Parent to the Company
relating to the loan to the Company.................................*
(c)(5) License Agreement, dated April 11, 1996, between Parent and the
Company.............................................................*
(c)(6) Joint Press Release, dated April 11, 1996, by Parent and the Company*
(c)(7) Confidentiality and Standstill Agreement, dated August 16, 1995,
between Dillon, Read & Co. Inc., on behalf of the Company, and
Parent..............................................................*
(d) None................................................................*
(e) Not Applicable......................................................*
(f) None................................................................*
* Previously Filed
Page 6 of 7 Pages
Pfizer Inc
235 East 42nd Street
New York, NY 10017
___________________
NEWS
For Immediate Release Contact:
May 15, 1996 Bob Fauteux (New York) (212) 573-3079
Andrew Heath (Brussels) 32-2-722-0853
PFIZER ACQUIRES 96.6% OF CORVITA CORPORATION
IN CASH TENDER OFFER
New York, May 15 -- Pfizer Inc (NYSE: PFE) announced that its wholly owned
subsidiary, HPG Acquisition Corp., has accepted for payment and made
arrangements to pay for approximately 6,918,487 shares of common stock, par
value $0.001 per share, of Corvita Corporation (Nasdaq: CVTAC). This results
from its cash tender offer for all outstanding shares of Corvita common stock,
at $10.25 net per share, which expired at 12:00 midnight, New York City time, on
May 14, 1996.
As a result of the tender offer, Pfizer now owns approximately 96.6% of the
outstanding common stock of Corvita. In approximately 30 days, under Florida
law, Pfizer plans to make Corvita a direct wholly-owned subsidiary. Corvita,
which develops, manufactures and markets synthetic vascular grafts, will operate
as a business of the Pfizer Hospital Products Group.
Pfizer Inc is a research-based, global health care company. In 1995, the company
reported sales of over $10 billion and expects to spend approximately $1.7
billion on research and development this year.
# # # # #
NYFS02...:\10\67610\0068\1716\REL5086I.53A
